CO2021017639A2 - Agonistas de il2 - Google Patents
Agonistas de il2Info
- Publication number
- CO2021017639A2 CO2021017639A2 CONC2021/0017639A CO2021017639A CO2021017639A2 CO 2021017639 A2 CO2021017639 A2 CO 2021017639A2 CO 2021017639 A CO2021017639 A CO 2021017639A CO 2021017639 A2 CO2021017639 A2 CO 2021017639A2
- Authority
- CO
- Colombia
- Prior art keywords
- polynucleotides
- polypeptides
- human
- host cells
- functional variant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención se refiere a variantes de interleucina-2 (IL2). En particular, la invención se refiere a un polipéptido que comprende una muteína de IL2 humana o de una variante funcional de IL2 humana, en donde la IL2 humana o variante funcional de la misma se sustituye tal que se mejora la afinidad para el complejo del receptor βγ IL2 (IL2Rβγ). En una forma de realización, la IL2 humana o variante funcional de la misma se sustituye adicionalmente tal que se reduce la afinidad para el complejo del receptor de αβγ IL2 (IL2Rαβγ). En una forma de realización, el polipéptido activa las células T efectoras sobre las células T reguladoras. La invención también se refiere a polinucleótidos que codifican para los polipéptidos de la invención, células hospederas que comprenden los polinucleótidos, composición farmacéuticas que comprenden los polipéptidos, polinucleótidos o células hospederas, métodos terapéuticos o profilácticos de tratamiento utilizando los polipéptidos, polinucleótidos, células hospederas o composición farmacéuticas y preparaciones médicas que comprenden los polipéptidos, polinucleótidos, células hospederas o composición farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2019066648 | 2019-06-24 | ||
PCT/EP2020/067479 WO2020260270A1 (en) | 2019-06-24 | 2020-06-23 | Il2 agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021017639A2 true CO2021017639A2 (es) | 2022-01-17 |
Family
ID=71103401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0017639A CO2021017639A2 (es) | 2019-06-24 | 2021-12-22 | Agonistas de il2 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20220356223A1 (es) |
EP (1) | EP3986916A1 (es) |
JP (1) | JP2022539543A (es) |
KR (1) | KR20220027864A (es) |
CN (1) | CN114450296A (es) |
AR (1) | AR119231A1 (es) |
AU (1) | AU2020308592A1 (es) |
BR (1) | BR112021026147A2 (es) |
CA (1) | CA3142911A1 (es) |
CL (1) | CL2021003437A1 (es) |
CO (1) | CO2021017639A2 (es) |
CU (1) | CU20210105A7 (es) |
IL (1) | IL288536A (es) |
MX (1) | MX2021015852A (es) |
TW (1) | TW202115105A (es) |
WO (1) | WO2020260270A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU20220020A7 (es) | 2022-03-18 | 2023-12-07 | Ct Inmunologia Molecular | Muteínas derivadas de la interleucina-2 humana con actividad superagonista |
WO2023180527A1 (en) | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
ES2655912T3 (es) | 2002-11-08 | 2018-02-22 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
EP1729795B1 (en) | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
ATE524493T1 (de) | 2006-07-24 | 2011-09-15 | Biorexis Pharmaceutical Corp | Exendin-fusionsproteine |
WO2008028977A2 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
EA201000979A1 (ru) | 2007-12-27 | 2011-02-28 | Новартис Аг | Улучшенные связывающие молекулы на основе фибронектина и их применение |
BRPI0913007A2 (pt) | 2008-05-02 | 2019-09-24 | Novartis Ag | moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas |
KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
CA2796338C (en) | 2010-04-13 | 2020-03-24 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
EP2673294B1 (en) * | 2011-02-10 | 2016-04-27 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
JP6592505B2 (ja) * | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
MX2021000801A (es) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
-
2020
- 2020-06-22 TW TW109121081A patent/TW202115105A/zh unknown
- 2020-06-23 WO PCT/EP2020/067479 patent/WO2020260270A1/en unknown
- 2020-06-23 MX MX2021015852A patent/MX2021015852A/es unknown
- 2020-06-23 CA CA3142911A patent/CA3142911A1/en active Pending
- 2020-06-23 CN CN202080046881.4A patent/CN114450296A/zh active Pending
- 2020-06-23 CU CU2021000105A patent/CU20210105A7/es unknown
- 2020-06-23 JP JP2021577041A patent/JP2022539543A/ja active Pending
- 2020-06-23 KR KR1020217042268A patent/KR20220027864A/ko unknown
- 2020-06-23 AU AU2020308592A patent/AU2020308592A1/en active Pending
- 2020-06-23 BR BR112021026147A patent/BR112021026147A2/pt unknown
- 2020-06-23 US US17/621,396 patent/US20220356223A1/en active Pending
- 2020-06-23 EP EP20733473.1A patent/EP3986916A1/en active Pending
- 2020-06-23 AR ARP200101777A patent/AR119231A1/es unknown
-
2021
- 2021-11-29 IL IL288536A patent/IL288536A/en unknown
- 2021-12-21 CL CL2021003437A patent/CL2021003437A1/es unknown
- 2021-12-22 CO CONC2021/0017639A patent/CO2021017639A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3142911A1 (en) | 2020-12-30 |
CU20210105A7 (es) | 2022-08-09 |
CN114450296A (zh) | 2022-05-06 |
KR20220027864A (ko) | 2022-03-08 |
IL288536A (en) | 2022-01-01 |
AU2020308592A1 (en) | 2022-01-06 |
JP2022539543A (ja) | 2022-09-12 |
US20220356223A1 (en) | 2022-11-10 |
BR112021026147A2 (pt) | 2022-05-10 |
MX2021015852A (es) | 2022-02-03 |
TW202115105A (zh) | 2021-04-16 |
WO2020260270A1 (en) | 2020-12-30 |
CL2021003437A1 (es) | 2022-09-23 |
AR119231A1 (es) | 2021-12-01 |
EP3986916A1 (en) | 2022-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021000811A8 (pt) | Agonistas de il2 | |
CO2021017639A2 (es) | Agonistas de il2 | |
AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
BR112018016281A2 (pt) | molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo | |
PE20140303A1 (es) | Polipeptidos interleuquina-2 mutantes | |
BR112019004764A2 (pt) | inibidores bicíclicos fundidos da interação menina-mll | |
BR112017019062A2 (pt) | conjugados de anticorpo-fármaco (adc) que se ligam a proteínas flt3 | |
BRPI0912411B8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune | |
BR112016029848A2 (pt) | proteínas de fusão mic-1 e utilizações das mesmas | |
AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
PE20150648A1 (es) | Proteinas de fusion para el tratamiento de un sindrome metabolico | |
CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
EA202192555A1 (ru) | Комбинированная терапия для лечения рака | |
BR112014021653A2 (pt) | Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica | |
BR112019023260A2 (pt) | Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos | |
BR0314450A (pt) | Sais de ácido borÈnico com adição de uma base farmaceuticamente aceitável, formulação farmacêutica, e uso dos referidos sais para preparar uma formulação farmacêutica | |
BR112021021284A2 (pt) | Composto, composição farmacêutica, e, métodos para o tratamento ou profilaxia de doenças inflamatórias da pele, doenças respiratórias, doenças gastrointestinais, doenças oculares, cânceres, doenças reumáticas, doenças desmielinizantes e doenças fibróticas e de inibição da atividade de proteínas de bromodomínio e domínio terminal extra | |
CO2020006886A2 (es) | Composición y método para tratar el linfoma periférico de linfocitos t y el linfoma cutáneo de linfocitos t | |
CO2021000210A2 (es) | Apirasas solubilizadas, métodos y usos | |
CL2023000087A1 (es) | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral | |
MX2022000713A (es) | Derivados de bencenosulfonamida y usos de las mismas. | |
BR112021021210A2 (pt) | Conjunto de polipeptídeos, método para gerar um polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico, segundo polipeptídeo precursor heterodimérico e composição farmacêutica | |
BR112022000155A2 (pt) | Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma | |
AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables | |
EA202190096A1 (ru) | Композиция, содержащая аналог соматостатина, для радиофармацевтического применения |